Compare RVMD & LII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RVMD | LII |
|---|---|---|
| Founded | 2014 | 1895 |
| Country | United States | United States |
| Employees | 883 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.2B | 15.8B |
| IPO Year | N/A | 1999 |
| Metric | RVMD | LII |
|---|---|---|
| Price | $149.27 | $483.09 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 19 | 13 |
| Target Price | $135.05 | ★ $566.58 |
| AVG Volume (30 Days) | ★ 2.4M | 380.4K |
| Earning Date | 05-06-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 1.00% |
| EPS Growth | N/A | ★ 1.11 |
| EPS | N/A | ★ 22.79 |
| Revenue | N/A | ★ $5,195,300,000.00 |
| Revenue This Year | N/A | $6.90 |
| Revenue Next Year | $411.49 | $5.73 |
| P/E Ratio | ★ N/A | $22.84 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $34.00 | $434.06 |
| 52 Week High | $148.00 | $689.44 |
| Indicator | RVMD | LII |
|---|---|---|
| Relative Strength Index (RSI) | 86.84 | 48.54 |
| Support Level | $93.39 | $481.66 |
| Resistance Level | N/A | $498.78 |
| Average True Range (ATR) | 4.31 | 18.54 |
| MACD | 6.04 | 7.48 |
| Stochastic Oscillator | 96.35 | 54.54 |
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.
Lennox International manufacturers and distributes heating, ventilating, air conditioning, and refrigeration products for the North American replacement (75% of sales) and new construction (25% of sales) markets. Residential HVAC (home comfort solutions) accounted for 67% of sales and commercial HVAC (building climate solutions) accounted for the remaining 33% of sales. To be clear, Lennox's commercial exposure is what its peers refer to as "residential and light commercial," lacks the scale and complexity of what is referred to as an "applied" solution. The company goes to market with multiple brands, but Lennox is the company's flagship HVAC brand.